multi-medicine platforms – Talk Bio

Actionable Insights Powered by AI

Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs

22 hours ago talkbio0Tagged Ascenta Capital, biotechs, Clinical Trials, Early-stage, Evan Rachlin, Funds, Investments, multi-medicine platforms, portfolio companies, venture capital

Ascenta Capital; biotech investment; venture capital; $325M fund; clinical trials; multi-medicine platforms; Evan Rachlin; Lorence Kim; early-stage biotechs; portfolio companies